Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) held its shareholders general meeting on June 25, 2026, in Paris at 2:30 p.m. CET.
Rhea-AI Summary
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) held its shareholders general meeting on June 25, 2026, in Paris at 2:30 p.m. CET.
Approximately 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board’s recommendations.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CLLS
On Jun 26, the first trading day after this news, CLLS closed 2.08% below the previous close.
Data tracked by StockTitan Argus for the Jun 26 session.
Key Figures
- Meeting date
- June 25, 2026
- Date of shareholders general meeting in Paris
- Meeting time
- 2:30 p.m. CET
- Scheduled time of shareholders general meeting
- Voting rights exercised
- 55,84%
- Proportion of voting rights exercised at the meeting
- Resolutions adopted
- 1 through 29
- Board-backed resolutions approved by shareholders
- Resolution rejected
- 30
- Only resolution not adopted, in line with board recommendations
- Meeting address
- 11 rue Watt, 4th floor, 75013 Paris
- Location of shareholders general meeting
Historical Context
-
Final Phase 1 lasme-cel and preliminary eti-cel data presented at EHA 2026.
-
FDA RMAT designation granted for lasme-cel in r/r B-ALL pivotal program.
-
Monthly disclosure of share count and total voting rights on Euronext Growth.
-
Announcement of annual shareholders general meeting scheduled for June 25, 2026.
-
Planned EHA 2026 presentations on lasme-cel and eti-cel clinical datasets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
At the meeting, during which approximately 55,
The detailed results of the vote and the resolutions are available on Cellectis’ website:
https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachments
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.